MétaCan
Menu
Back to cohort
Record W4382344222 · doi:10.1503/cjs.017020

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

2023· article· en· W4382344222 on OpenAlexafffundvenue
Taymaa May, Marcus Q. Bernardini, Stéphanie Lheureux, Katja K.H. Aben, Elisa V. Bandera, Matthias W. Beckmann, Javier Benı́tez, Andrew Berchuck, Line Bjørge, Michael E. Carney, Daniel W. Cramer, Anna DeFazio, Thilo Dörk, Michael Friedländer, María J. García, Ellen L. Goode, Alexander Hein, Claus Høgdall, Allan Jensen, Sharon E. Johnatty, Catherine J. Kennedy, Lambertus A. Kiemeney, Susanne K. Kjær, Jolanta Kupryjańczyk, Keitaro Matsuo, Valerie McGuire, Francesmary Modugno, Lisa E. Paddock, Tanja Pejović, Catherine M. Phelan, Marjorie J. Riggan, Cristina Rodríguez‐Antona, Joseph H. Rothstein, Weiva Sieh, Honglin Song, Kathryn L. Terry, Anne M. van Altena, Adriaan Vanderstichele, Ignace Vergote, Liv Cecilie Vestrheim Thomsen, Penelope M. Webb, Nicolas Wentzensen, Lynne R. Wilkens, Argyrios Ziogas, Haiyan Jiang, Alicia Tone

Bibliographic record

VenueCanadian Journal of Surgery · 2023
Typearticle
Languageen
FieldMedicine
TopicOvarian cancer diagnosis and treatment
Canadian institutionsAstraZeneca (Canada)Princess Margaret Cancer Centre
FundersDivision of Cancer Epidemiology and Genetics, National Cancer InstituteMedical Research and Materiel CommandDavid Geffen School of Medicine, University of California, Los AngelesNational Center for Advancing Translational SciencesNational Center for Research ResourcesNational Institute of Environmental Health SciencesRadboud Institute for Health SciencesNational Health and Medical Research CouncilMedical Research CouncilInstituto de Salud Carlos IIIKnight Cancer Institute, Oregon Health and Science UniversityDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of PittsburghSchool of Medicine, Stanford UniversityNational Institutes of HealthNational Cancer InstituteCancer Institute NSWPeter MacCallum FoundationRutgers Cancer Institute of New JerseyNSW Ministry of HealthMedizinischen Hochschule HannoverQIMR Berghofer Medical Research InstituteUniversity of SydneyNorges ForskningsrådMinistry of Health, Labour and WelfareUniversitetet i BergenKræftens BekæmpelseRigshospitaletOvarian Cancer Research FundMinisterio de Economía y CompetitividadBundesministerium für Bildung und ForschungOvarian Cancer ActionUniversity of SouthamptonU.S. Department of DefenseCancer Research UKUniversity of CambridgeFred C. and Katherine B. Andersen FoundationUniversity of California, IrvineKreftforeningenCancer Research SocietyMissouri Department of Health and Senior ServicesMinnesota Ovarian Cancer AllianceMoffitt Cancer CenterDeutsches KrebsforschungszentrumRoswell Park Cancer InstituteNational Institute for Health and Care ResearchHarvard T.H. Chan School of Public HealthUniversity of PittsburghLon V. Smith FoundationRadboud UniversiteitUniversity of PennsylvaniaMayo Foundation for Medical Education and ResearchOregon Health and Science UniversityOvarian Cancer AustraliaBrigham and Women's HospitalState of New Jersey Department of HealthAstraZenecaCancer AustraliaRadboud Universitair Medisch CentrumHelse VestMagee-Womens Research Institute
KeywordsMedicineOvarian carcinomaOncologyInternal medicineSerous fluidSerous carcinomaSurvival analysisCarcinomaGynecologyOvarian cancerCancer

Abstract

fetched live from OpenAlex

BACKGROUND: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. METHODS: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. RESULTS: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. CONCLUSION: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.003
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.051
GPT teacher head0.312
Teacher spread0.261 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2023
Admission routes3
Has abstractyes

Explore more

Same venueCanadian Journal of SurgerySame topicOvarian cancer diagnosis and treatmentFrench-language works237,207